REVA Medical will stay in a voluntary suspension until 30 June, the company announced this morning. It has received emergency funding of $3 million from existing lenders to help with "immediate financial needs on an interim basis", but is in discussions about a broader restructure. Chief executive Reggie Groves has resigned, Jeff Anderson has been promoted. Doctor Stephen Oesterle will become a strategic advisor and resign from the board.
Chairman C Raymond Larkin, Jr, said "Following a comprehensive review with the assistance of our outside advisors, REVA has entered into an agreement with a group of existing debt and equity holders to fund the company's near-term operations. This funding helps to ensure REVA has sufficient time to pursue long-term financial solutions that serve the interests of our many constituents - including patients, customers, employees, creditors, and shareholders".
REVA went into a voluntary suspension on 20 February when it was trading at 17 cents.